For Research Use Only — Not for human or veterinary use.

Education

TB-500: Research Overview of the Actin-Binding Peptide

Chemistry, proposed mechanism, and the research domains — cardiac, ophthalmic, and general tissue repair — where the Thymosin Beta-4 fragment appears most in the literature.

BPC-157 & TB-500
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • TB-500 is a synthetic fragment corresponding to the actin-binding region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein.[1]
  • The actin-binding domain — a short 7-amino-acid sequence (Ac-LKKTETQ) — was reported as both necessary and sufficient to reproduce Tβ4's angiogenic effect in vitro.[1]
  • In cardiac research models, Tβ4 has been reported to activate integrin-linked kinase and promote cardiomyocyte migration and survival.[2]
  • A separate body of literature examines Tβ4 in corneal wound healing and ocular surface research, distinct from its cardiac and musculoskeletal research applications.[3]
  • Researchers note that TB-500 is not structurally identical to full-length Tβ4, and some literature attributes reported wound-healing activity to a related metabolite rather than the parent peptide.[4]

What It Is

TB-500 is a synthetic peptide corresponding to a fragment of Thymosin Beta-4 (Tβ4), a small, naturally occurring 43-amino-acid protein found across many cell types. Tβ4's core biochemical function is binding and sequestering G-actin (the monomeric form of the cytoskeletal protein actin), which regulates cell migration, angiogenesis, and wound-repair processes studied across multiple tissue types.[1] Research specifically identifies a short 7-amino-acid actin-binding sequence (Ac-LKKTETQ) within the larger protein as responsible for much of this activity — TB-500 is designed around this active region.[1]

Mechanism & Pathway

The actin-binding domain of Tβ4 was reported by Philp and colleagues to be both necessary and sufficient for promoting angiogenesis (new blood vessel formation) in vitro, establishing the actin-sequestering mechanism as central to the peptide's studied effects on cell migration.[1] In cardiac research models, full-length Tβ4 has separately been reported to activate integrin-linked kinase (ILK), a signaling protein involved in cell adhesion, and to promote the migration and survival of cardiac cell populations following simulated injury.[2] Researchers have noted an important nuance: TB-500 is not structurally identical to full-length Tβ4, and some literature discussing TB-500's specific wound-healing activity attributes it to a related metabolite (Ac-LKKTE) rather than the parent peptide itself — a distinction worth checking when comparing studies that use full-length Tβ4 versus the shorter TB-500 fragment.[4]

Research Domains

  • Angiogenesis & cell-migration research — in vitro studies isolated the actin-binding domain as necessary and sufficient for driving new blood vessel formation.[1]
  • Cardiac repair research — animal models of cardiac injury report Tβ4-driven activation of integrin-linked kinase, associated with improved cardiomyocyte migration and survival.[2]
  • Corneal & ocular surface research — a separate literature strand examines Tβ4 in corneal wound healing and anti-inflammatory research contexts, distinct from cardiac and musculoskeletal applications.[3]
  • General tissue repair & regeneration research — broader animal-model reviews describe Tβ4 activity across multiple tissue-repair contexts, summarizing its multifunctional research profile.[4]

Comparative Notes

TB-500 is frequently studied and sold alongside BPC-157 in combined-compound tissue-repair research, including as a pre-blended vial in this catalog. Mechanistically the two are distinct: TB-500 acts primarily through G-actin sequestration affecting cytoskeletal dynamics and cell migration, while BPC-157's most-reported pathways run through VEGFR2/angiogenesis and growth-hormone-receptor signaling. The two are studied together based on this complementary-mechanism rationale rather than a shared pathway.

BPC-157 & TB-500 product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for a TB-500 research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. PMID: 14500546
  2. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. PMID: 15565145
  3. Sosne G, Qiu P, Kurpakus-Wheater M (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. PMID: 19668473
  4. Philp D, Kleinman HK (2010). Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences. PMID: 20536453

FAQ

TB-500 is a synthetic fragment corresponding to the actin-binding region of Thymosin Beta-4, a naturally occurring 43-amino-acid protein.[1]

Research centers on G-actin sequestration via a short actin-binding sequence, reported as necessary and sufficient for angiogenic effects in vitro.[1]

No — TB-500 corresponds to a fragment of the full-length protein, and some literature attributes TB-500-specific wound-healing activity to a related metabolite rather than the parent peptide, a distinction worth noting when comparing studies.

Published research spans angiogenesis/cell-migration, cardiac repair, corneal/ocular surface, and general tissue-repair research models.[1][2][3]

The two are mechanistically distinct: TB-500 acts through G-actin sequestration affecting cytoskeletal dynamics, while BPC-157 is most associated with VEGFR2/angiogenesis and growth-hormone-receptor signaling. They are frequently studied together in combined-compound research.

No. TB-500 is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance.

Related Guides